2,559,090 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by ICONIQ Capital LLC

ICONIQ Capital LLC bought a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,559,090 shares of the company’s stock, valued at approximately $4,350,000. ICONIQ Capital LLC owned 1.38% of Neumora Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. HBK Sorce Advisory LLC bought a new position in shares of Neumora Therapeutics during the 2nd quarter worth about $26,000. Hsbc Holdings PLC bought a new position in shares of Neumora Therapeutics during the fourth quarter valued at $27,000. Virtu Financial LLC acquired a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at $31,000. Fred Alger Management LLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter worth about $40,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Neumora Therapeutics in the 2nd quarter worth about $41,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Price Performance

NMRA stock opened at $1.63 on Monday. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 4.50. Neumora Therapeutics, Inc. has a one year low of $0.83 and a one year high of $3.65. The stock has a market cap of $306.28 million, a PE ratio of -1.33 and a beta of 2.75. The firm has a 50 day simple moving average of $1.60 and a two-hundred day simple moving average of $2.11.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. On average, analysts predict that Neumora Therapeutics, Inc. will post -0.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Daljit Singh Aurora sold 21,055 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $1.60, for a total transaction of $33,688.00. Following the completion of the transaction, the insider directly owned 48,750 shares in the company, valued at $78,000. This trade represents a 30.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 453,833 shares of company stock valued at $701,219 over the last 90 days. Insiders own 26.94% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Wall Street Zen raised Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Mizuho dropped their price objective on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Thursday, June 18th. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Weiss Ratings lowered shares of Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. Finally, Royal Bank Of Canada lowered their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Neumora Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $6.57.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.